The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: A powerful molecular adjuvant for DNA anti-tumor vaccination

Vaccine

Volumn 28, Issue 42, 2010, Pages 6891-6900

  Ni, Jing ^a   Schirrmacher, Volker ^a,b   Fournier, Philippe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b IOZK   (Germany)

Author keywords

Adjuvant; Humoral and cellular immunities; Immune response; Immunomodulation; Tumor therapy; Vaccination

Indexed keywords

BETA GALACTOSIDASE; CANCER VACCINE; DNA VACCINE; EPITHELIAL CELL ADHESION MOLECULE; IMMUNOLOGICAL ADJUVANT; PLASMID DNA; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; VIRUS SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CARCINOMA CELL; CELLULAR IMMUNITY; CISTRON; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMORAL IMMUNITY; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; T LYMPHOCYTE; TUMOR MODEL; TUMOR REGRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL ADHESION MOLECULES; CELL LINE; CROSS PROTECTION; FEMALE; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEURAMINIDASE; NEWCASTLE DISEASE VIRUS; PLASMIDS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 77956883751     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.011     Document Type: Article

References (65)

1. Pardoll D.M. Cancer vaccines. Nat Med 1998, 4:525-531.
2. Houghton A.N. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994, 180:1-4.
3. Abdallah B., Sachs L., Demeneix B.A. Non-viral gene transfer: applications in developmental biology and gene therapy. Biol Cell 1995, 85(1):1-7.
4. Verma I.M., Somia N. Gene therapy-promises, problems and prospects. Nature 1997, 389(6648):239-242.
5. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993, 90(24):11478-11482.
6. Robinson H.L., Hunt L.A., Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993, 11(9):957-960.
7. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102):1745-1749.
8. Bodles-Brakhop A.M., Draghia-Akli R. DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 2008, 7(7):1085-1101.
9. Chiarella P., Massi E., De Robertis M., Fazio V.M., Signori E Strategies for effective naked-DNA vaccination against infectious diseases. Recent Pat Antiinfect Drug Discov 2008, 3(2):93-101.
10. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
11. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5:505-517.
12. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine 2001, 19:2647-2656.
13. Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006, 5:803-825.
14. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 2003, 8:934-943.
15. Stevenson F.K. DNA vaccines and adjuvants. Immunol Rev 2004, 199:5-8.
16. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 2004, 199:227-250.
17. Shedlock D.J., Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000, 68(6):793-806.
18. Nagai Y., Hamaguchi M., Toyoda T. Molecular biology of Newcastle Disease Virus. Prog Vet Microbiol Immunol 1989, 5:16-64.
19. Zeng J., Fournier P., Schirrmacher V. Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction. J Mol Med 2002, 80:443-451.
20. Fournier P., Zeng J., Von Der Lieth C.W., Washburn B., Ahlert T., Schirrmacher V. Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus. Int J Oncol 2004, 24:623-634.
21. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005, 54(6):587-598.
22. Schulze T., Kemmner W., Weitz J., Wernecke K.D., Schirrmacher V., Schlag P.M. Efficiency of adjuvant active specific immunization with Newcastle Disease Virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 2009, 58(1):61-69.
23. Seligson D.B., Pantuck A.J., Liu X., Huang Y., Horvath S., Bui M.H., et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 2004, 10:2659-2669.
24. Went P.T., Lugli A., Meier S., Bundi M., Mirlacher M., Sauter G., et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004, 35:122-128.
25. Zeng J., Fournier P., Schirrmacher V. High cell surface expression of Newcastle Disease Virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int J Oncol 2004, 25:293-302.
26. Ni J., Nolte B., Vandermeulen G., Preat V., Scherman D., Schirrmacher V., et al. Ear pinna: a privileged DNA electroporation site for inducing strong Th1 immune responses. Open Cancer Immunol J 2009, 2:1-13.
27. McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007, 27:687-690.
28. Roman L.D., Wilczynski S., Muderspach L.I., Burnett A.F., O'Meara A., Brinkman J.A., et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007, 106:558-566.
29. Zhang X., Yu C., Zhao J., Fu L., Yi S., Liu S., et al. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J Gene Med 2007, 9:715-726.
30. Einstein M.H., Kadish A.S., Burk R.D., Kim M.Y., Wadler S., Streicher H., et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007, 106:453-460.
31. Gupta R.K., Singh M., O'Hagan D.T. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev 1998, 32:225-246.
32. Sapin A., Clavreul A., Garcion E., Benoit J.P., Menei P. Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma. J Neurosurg 2006, 105:745-752.
33. Lo-Man R., Rueda P., Sedlik C., Deriaud E., Casal I., Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 1998, 28:1401-1407.
34. Kaufmann A.M., Nieland J.D., Jochmus I., Baur S., Friese K., Gabelsberger J., et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007, 121:2794-2800.
35. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344:873-875.
36. Medzhitov R., Janeway C.A. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997, 9(1):4-9.
37. Kim T.S., DeKruyff R.H., Rupper R., Maecker H.T., Levy S., Umetsu D.T. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen specific IgE production. J Immunol 1997, 158:4137-4144.
38. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60:1035-1042.
39. Kwissa M., Unsinger J., Schirmbeck R., Hauser H., Reimann J. Polyvalent DNA vaccines with bidirectional promoters. J Mol Med 2000, 78:495-506.
40. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13:114-119.
41. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006, 124:849-863.
42. Ishii K.J., Kawagoe T., Koyama S., Matsui K., Kumar H., Kawai T., et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008, 451(7179):725-729.
43. Babiuk S., Mookherjee N., Pontarollo R., Griebel P., van Drunen Littel-van den Hurk S., Hecker R., et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 2004, 113(1):114-120.
44. Spies B., Hochrein H., Vabulas M., Huster K., Busch D.H., Schmitz F., et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003, 171(11):5908-5912.
45. Kondo T., Nakazawa H., Ito F., Hashimoto Y., Osaka Y., Futatsuyama K., et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006, 97(8):780-786.
46. Lin C.C., Yen M.C., Lin C.M., Huang S.S., Yang H.J., Chow N.H., et al. Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer. J Gene Med 2008, 10(6):679-689.
47. Forg P., von Hoegen P., Dalemans W., Schirrmacher V Superiority of the ear pinna over muscle tissue as site for DNA vaccination. Gene Ther 1998, 5:789-797.
48. Schirmacher V., Forg P., Dalemans W., Chlichlia K., Zeng Y., Fournier P., et al. Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. Gene Ther 2000, 7:1137-1147.
49. Weber L.W., Bowne W.B., Wolchok J.D., Srinivasan R., Qin J., Moroi Y., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998, 102:1258-1264.
50. Bowne W.B., Srinivasan R., Wolchok J.D., Hawkins W.G., Blachere N.E., Dyall R., et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999, 190:1717-1722.
51. Hawkins W.G., Gold J.S., Dyall R., Wolchok J.D., Hoos A., Bowne W.B., et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000, 128:273-280.
52. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R., Borden E.C., Bordens R., et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998, 58:2489-2499.
53. Sun S., Zhang X., Tough D.F., Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998, 188:2335-2342.
54. Marrack P., Kappler J., Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999, 189:521-530.
55. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells: enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978, 147:1299-1313.
56. Zeng J., Fournier P., Schirrmacher V. Induction of interferon and tumor necrosis factor-related apoptosis-inducing blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle Disease Virus. Virology 2002, 297:19-30.
57. Zeng J., Fournier P., Schirrmacher V. Stimulation of human natural interferon-response via paramyxo-virus hemagglutinin lectin-cell interaction. J Mol Med 2002, 80:443-451.
58. LeBon A., Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002, 14:432-526.
59. Tough D.F. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 2004, 45(2):257-264.
60. Gigante M., Mandic M., Wesa A.K., Cavalcanti E., Dambrosio M., Mancini V., et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 2008, 31(3):254-262.
61. Fournier P., Arnold A., Schirrmacher V. Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. J BUON 2009, 14(Suppl. 1):S111-S122.
62. Ni J., Nolte B., Arnold A., Fournier P., Schirrmacher V. Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence. Vaccine 2009, 27(40):5480-5487.
63. Jarahian M., Watzl C., Fournier P., Arnold A., Djandji D., Zahedi S., et al. Activation of natural killer cells by Newcastle Disease Virus hemagglutinin-neuraminidase. J Virol 2009, 83(16):8108-8121.
64. Ertel C., Millar N.S., Emmerson P.T., Schirrmacher V., von Hoegen P. Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. Eur J Immunol 1993, 23:2592-2596.
65. Haas C., Ertel C., Gerhards R., Schirrmacher V. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. Int J Oncol 1998, 13:1105-1115.